biostudies-literatureUnknown14(1)Zhang SHuman epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-muThoracic cancer91-104https://www.ebi.ac.uk/biostudies/studies/S-EPMC9807451biostudies-literatureChinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.PMC9807451Wu JShi LWu LZhang JDong XHuang JLu YHu XWang DLin XDu YWang GHuang LWang HZhang SGao FWang JWang KShi XWang LZhan PWan BRao CWang QSun PGuo HWang WKang JZhang CWang ZChu QXia YXie YYang NXu CZhong WYao WYuan JLi WMin LYuan DLi XYang ZLi ZLi SFeng HLin GXu TYao CGao WPu XPang FLiu HLiu JMa SMeng RZhu ZZhu YTang CCai JJia HYu GYu JMiao LNiu XLiu XJiang ZLiu ZYao YZhou CYu ZSong ZNie XZhou JSong YPan WLv DZhou WYe MFang YLuo JZhang YHong ZFang WZhang XLiu ALv TFang MCai XfalseChinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mu2023-01-01T00:00:00Z2023 Jan2025-04-04T10:58:59.39Z2025-04-04T10:58:59.39ZS-EPMC98074513644414310.1111/1759-7714.14743